Pyxis Oncology, INC

Market Movers (8-K)

See all →
NASDAQ
Pyxis Oncology announced updated Phase 1 data for its investigational drug MICVO, demonstrating a 39% confirmed objective response rate and a median duration of response of 9.2 months in patients with recurrent/metastatic head and neck squamous cell carcinoma.
Better than expected
NASDAQ
Pyxis Oncology announced third quarter 2026 financial results, highlighting progress in its micvotabart pelidotin (MICVO) development for head and neck cancer and a strengthened balance sheet.
Capital raise
NASDAQ
Pyxis Oncology, Inc. has entered into an underwriting agreement for a public offering of common stock and warrants, raising approximately $102.8 million.
Capital raise
NASDAQ
Pyxis Oncology announced updated Phase 1 data for its drug candidate micvotabart pelidotin (MICVO) in head and neck cancer, showing a 36% objective response rate and a 94% disease control rate.
Better than expected
NASDAQ
Pyxis Oncology has appointed Thomas Civik as its permanent Chief Executive Officer and Chairman of the Board, effective September 4, 2026, reinforcing its focus on advancing its MICVO program.
NASDAQ
Pyxis Oncology reported Q2 2026 results, announcing a private placement financing of up to $114 million, with approximately $50 million upfront, extending its cash runway into Q2 2027 and providing updates on its MICVO clinical program.
Capital raise

Quarterly Earnings (10-Q)

See all →
NASDAQ
Pyxis Oncology's Q3 2026 Form 10-Q details continued operating losses, a strong cash position post-financing, and positive interim data for its lead oncology candidate, MICVO.
Capital raise
NASDAQ
Pyxis Oncology reports continued operating losses and substantial R&D expenses, raising concerns about its ability to continue as a going concern despite a recent private placement.
Worse than expected
Capital raise
NASDAQ
Pyxis Oncology filed its Q1 2026 Form 10-Q, detailing a net loss of $23.3 million and highlighting progress in its MICVO clinical development programs.
Worse than expected
Capital raise
NASDAQ
Pyxis Oncology reported increased net losses and a going concern warning, while advancing its lead oncology candidate, micvotabart pelidotin, with positive preliminary HNSCC clinical data and Fast Track Designation.
Capital raise
Worse than expected
NASDAQ
Pyxis Oncology reported increased losses in Q2 2025 but highlighted positive clinical data and Fast Track designation for its lead oncology candidate, micvotabart pelidotin.
Capital raise
NASDAQ
Pyxis Oncology's Q1 2025 results show a net loss of $21.2 million, with strategic focus shifting towards advancing micvotabart pelidotin, particularly in R/M HNSCC.
Worse than expected

Annual Reports (10-K)

NASDAQ
Pyxis Oncology announced positive preliminary Phase 1 data for its lead oncology candidate MICVO in HNSCC, both as monotherapy and in combination with KEYTRUDA, but reported significant losses and substantial doubt about its ability to continue as a going concern.
Capital raise
Worse than expected
NASDAQ
Pyxis Oncology focuses on advancing its lead candidate, micvotabart pelidotin, for head and neck cancer treatment following encouraging Phase 1 trial results, while reporting a net loss of $77.3 million for 2024.
Capital raise
Worse than expected
NASDAQ
Pyxis Oncology's annual 10-K filing details the company's clinical progress, financial status, and strategic direction, highlighting its focus on novel cancer therapeutics.
Worse than expected
Capital raise

Insider Trading (Form 4)

See all →
NASDAQ
Rachel Humphrey, a Director of Pyxis Oncology, Inc., received 34,500 shares of common stock on November 6, 2026.
NASDAQ
GordonMD Global Investments LP and 3 others reported changes in beneficial ownership of Pyxis Oncology, Inc. common stock on October 1, 2026.
NASDAQ
GordonMD Global Investments LP and 3 others reported changes in beneficial ownership of Pyxis Oncology, Inc. common stock on October 1, 2026.
NASDAQ
Thomas Civik, CEO & Chairman of the Board and a Director of Pyxis Oncology, Inc., received 2,503,050 shares of common stock on September 4, 2026.
NASDAQ
Jakob Dupont, a Director of Pyxis Oncology, Inc., received 46,000 shares of common stock on August 20, 2026.
NASDAQ
Jakob Dupont, a Director at Pyxis Oncology, Inc., was granted 45,867 stock options with an exercise price of $1.36.

Proxy Statements (Def-14A)

See all →
NASDAQ
Pyxis Oncology, Inc. has announced its 2026 Annual Meeting of Stockholders will be held virtually on June 15, 2026, to elect directors and ratify auditor appointment.
NASDAQ
Pyxis Oncology will hold its annual stockholders meeting on June 11, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.
NASDAQ
Pyxis Oncology announces its 2025 Annual Meeting of Stockholders to be held virtually on June 18, 2025, featuring proposals for director elections and auditor ratification.
NASDAQ
Pyxis Oncology is asking stockholders to approve an amendment to its 2021 Equity and Incentive Plan to increase the available shares by 5,500,000 at a special meeting on October 23, 2024.
NASDAQ
Pyxis Oncology will hold its annual stockholders meeting on June 11, 2024, to elect directors and ratify the appointment of Ernst & Young LLP as its independent accounting firm.
NASDAQ
Pyxis Oncology announces its 2024 Annual Meeting of Stockholders to be held virtually on June 11, 2024, to vote on director elections and the ratification of its independent accounting firm.

Schedule 13D - Activist Investments

NASDAQ
Pyxis Oncology, Inc.'s President, CEO, and Chief Medical Officer, Lara Sullivan, has increased her beneficial ownership to 11.21% of the company's common stock following a new stock option grant.

Schedule 13G - Passive Investments

See all →
NASDAQ
RTW Investments, LP and Roderick Wong have jointly filed a Schedule 13G, reporting beneficial ownership of 9.9% of Pyxis Oncology, Inc. common stock.
NASDAQ
Laurion Capital Management LP, along with individuals Benjamin Alexander Smith and Janaka Sheehan Maduraperuma, has reported beneficial ownership of over 5% of Pyxis Oncology, Inc. common stock.
NASDAQ
GordonMD Global Investments LP and affiliated entities have updated their Schedule 13G filing, reporting beneficial ownership of 16.4% of Pyxis Oncology, Inc. common stock.
NASDAQ
Coastlands Capital and affiliated entities have jointly filed a Schedule 13G, reporting beneficial ownership of 5.42% of Pyxis Oncology's common stock as of October 1, 2026.
NASDAQ
GordonMD Global Investments LP and associated entities have updated their Schedule 13G filing concerning Pyxis Oncology, Inc., reporting beneficial ownership of 17.5% of the common stock.
NASDAQ
Several Biotechnology Value Funds and Mark N. Lampert have jointly filed a Schedule 13G, disclosing beneficial ownership of Pyxis Oncology, Inc. common stock and warrants.